MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 111 transactions totaling $1.0M, demonstrating a bearish sentiment with -$820.7K in net insider flow. The most recent transaction on Apr 3, 2018 involved a transaction of 513 shares valued at $0.
No significant insider buying has been recorded for MBVX in the recent period.
No significant insider selling has been recorded for MBVX in the recent period.
Based on recent SEC filings, insider sentiment for MBVX is bearish with an Insider Alignment Score of 10/100 and a net flow of -$820.7K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading MBVX stock, having executed 111 transactions in the past 90 days. The most active insider is John David Hansen (Executive), who has made 20 transactions totaling $282.6K.
Get notified when executives and directors at MBVX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 3, 2018 | C. Varvaro Thomas | Executive | Option Exercise | 513 | $N/A | $0 | |
| Apr 2, 2018 | David Hansen John | Executive | Option Exercise | 13,561 | $N/A | $0 | |
| Apr 2, 2018 | David Hansen John | Executive | Payment | 4,689 | $N/A | $0 | |
| Apr 2, 2018 | P. Hanson Gregory | Executive | Option Exercise | 7,021 | $N/A | $0 | |
| Apr 2, 2018 | P. Hanson Gregory | Executive | Payment | 2,428 | $N/A | $0 | |
| Apr 2, 2018 | W. Maffuid Paul | Executive | Payment | 1,735 | $N/A | $0 | |
| Apr 2, 2018 | W. Maffuid Paul | Executive | Option Exercise | 5,015 | $N/A | $0 | |
| Apr 2, 2018 | M. Cohen Kenneth | Executive | Option Exercise | 513 | $N/A | $0 | |
| Apr 2, 2018 | Maier Paul V | Executive | Option Exercise | 513 | $N/A | $0 | |
| Apr 2, 2018 | Maier Paul V | Executive | Option Exercise | 513 | $N/A | $0 | |
| Apr 2, 2018 | M. Cohen Kenneth | Executive | Option Exercise | 513 | $N/A | $0 | |
| Jan 24, 2018 | M. Cohen Kenneth | Executive | Sale | 17,996 | $0.84 | $15.1K | |
| Jan 24, 2018 | Maier Paul V | Executive | Sale | 17,999 | $0.84 | $15.1K | |
| Jan 24, 2018 | C. Varvaro Thomas | Executive | Sale | 17,996 | $0.84 | $15.1K | |
| Jan 24, 2018 | F. Eisenberg Jeffrey | Executive | Sale | 17,998 | $0.84 | $15.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 50 | $920.1K | 90.2% |
Purchase(P) | 17 | $99.4K | 9.8% |
Exercise(M) | 34 | $0 | 0.0% |
Payment(F) | 7 | $0 | 0.0% |
Award(A) | 3 | $0 | 0.0% |
Insider selling pressure at MABVAX THERAPEUTICS HOLDINGS, INC. has increased, with 13 insiders executing 111 transactions across all time. Total sales of $920.1K significantly outpace purchases of $99.4K, resulting in a net outflow of $820.7K. This selling activity appears largely discretionary, which may warrant closer attention from investors.